Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
Rajiv Agarwal, Arjun D Sinha, Andrew E Cramer...
https://pubmed.ncbi.nlm.nih.gov/34739197Actively Recruiting
Phase 4
Age: 18Years +
All Genders
ID07271420
Blood Pressure Control With Thiazide Diuretics in Patients on Peritoneal Dialysis
Led by Chinese University of Hong Kong · Updated on 2025-12-09
40
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the blood pressure lowering effects of thiazide diuretics in patients who are on chronic peritoneal dialysis and have uncontrolled hypertension. This study is a prospective, single-center treatment-withdrawal crossover trial involving 10 participants. It focuses on evaluating changes in systolic and diastolic blood pressure over a 90-day period. Participants will first receive oral hydrochlorothiazide 25 mg once daily along with their standard treatment for 90 days. After this treatment phase, there will be a 14-day washout period without the drug, followed by a 90-day control period where no intervention is given. The study aims to compare blood pressure and other health markers during these periods. Throughout the study, participants will be monitored for changes in blood pressure, body weight, body composition using bio impedance spectroscopy, and urinary sodium excretion. The primary outcome is the change in systolic and diastolic blood pressure after 90 days. Safety and health status will be observed, and the total participation involves treatment and control phases separated by a washout period.
CONDITIONS
Brief Title
Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patients on chronic peritoneal dialysis with uncontrolled hypertension (systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg)
- Adults aged 18 years or older
You will not qualify if you...
- Life expectancy less than 3 months
- Planned conversion to hemodialysis within 3 months
- Scheduled kidney transplantation within 3 months or less
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 90 days
Participants receive oral hydrochlorothiazide once daily in addition to their standard treatment.
Visits as per treatment schedule
Washout Period
Duration - 14 days
Participants stop taking hydrochlorothiazide to allow the drug to clear from their system.
Visits at start and end of washout
Control Period
Duration - 90 days
Participants do not receive hydrochlorothiazide and continue standard treatment alone.
Visits as per control schedule
Trial Site Locations
Total: 1 location
1
Prince of Wales Hospital. The Chinese University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Loading map...
Research Team
G
Gordon Chan, MD, MRCP
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Revisiting diuretic choice in chronic kidney disease.
Sehrish Ali, Sankar D Navaneethan, Salim S Virani...
https://pubmed.ncbi.nlm.nih.gov/35894274Prevalence of Apparent Treatment-Resistant Hypertension in Chronic Kidney Disease in Two Large US Health Care Systems.
Jaejin An, Manjula Kurella Tamura, Michelle C Odden...
https://pubmed.ncbi.nlm.nih.gov/36400564Polypharmacy Predicts Onset and Transition of Frailty, Malnutrition, and Adverse Outcomes in Peritoneal Dialysis Patient.
G C-K Chan, J K-C Ng, K-M Chow...
https://pubmed.ncbi.nlm.nih.gov/36519768